GlassScriptPhysician profile
Amy D Gordon
NPI 1164798989
$3,703.04
in general payments reported to CMS, 2019-2025
20 companies · $691 in 2025
The $691 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $661 · 2022: $585 · 2023: $778 · 2024: $987 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $812.48 | 2021-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $606.29 | 2021-2025 | |
| Amgen INC. | $540.46 | 2021-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $480.05 | 2021-2023 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $340.99 | 2023-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.75 | 2024-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $106.42 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $96.08 | 2021-2022 | |
| Horizon Therapeutics Plc | $69.33 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $46.82 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $44.15 | 2024 | Lupkynis |
| Ardelyx, INC. | $41.10 | 2024 | Ibsrela |
| Fresenius USA Marketing, INC. | $39.66 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $31.91 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $29.25 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $25.32 | 2022-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $24.34 | 2025 | Ultomiris |
| Novo Nordisk INC | $21.70 | 2025 | |
| Vifor Pharma, INC. | $15.51 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $15.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.